These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36736528)

  • 1. Glutamate ionotropic receptor NMDA type subunit 1: A novel potential protein target of dapagliflozin against renal interstitial fibrosis.
    Liu Y; Wang Y; Chen S; Bai L; Li F; Wu Y; Zhang L; Wang X
    Eur J Pharmacol; 2023 Mar; 943():175556. PubMed ID: 36736528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation into the effect and mechanism of dapagliflozin against renal interstitial fibrosis based on transcriptome and network pharmacology.
    Liu Y; Wang Y; Chen S; Bai L; Xie X; Zhang L; Wang X
    Int Immunopharmacol; 2022 Nov; 112():109195. PubMed ID: 36070627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
    Terami N; Ogawa D; Tachibana H; Hatanaka T; Wada J; Nakatsuka A; Eguchi J; Horiguchi CS; Nishii N; Yamada H; Takei K; Makino H
    PLoS One; 2014; 9(6):e100777. PubMed ID: 24960177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanisms.
    Afsar B; Afsar RE
    Pharmacol Rep; 2023 Feb; 75(1):44-68. PubMed ID: 36534320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RGS1 mediates renal interstitial fibrosis through activation of the inflammatory response.
    Lu T; Chen S; Xu J
    Arch Biochem Biophys; 2023 Dec; 750():109744. PubMed ID: 37696381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney.
    Ke Q; Shi C; Lv Y; Wang L; Luo J; Jiang L; Yang J; Zhou Y
    FASEB J; 2022 Jan; 36(1):e22078. PubMed ID: 34918381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hirudin improves renal interstitial fibrosis by reducing renal tubule injury and inflammation in unilateral ureteral obstruction (UUO) mice.
    Xie Y; Lan F; Zhao J; Shi W
    Int Immunopharmacol; 2020 Apr; 81():106249. PubMed ID: 32066115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Demethylzeylasteral protects against renal interstitial fibrosis by attenuating mitochondrial complex I-mediated oxidative stress.
    Shen P; Deng X; Li T; Chen X; Wu X
    J Ethnopharmacol; 2024 Jun; 327():117986. PubMed ID: 38437887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of circular RNAs and functional competing endogenous RNA networks in human proximal tubular epithelial cells treated with sodium-glucose cotransporter 2 inhibitor dapagliflozin in diabetic kidney disease.
    Song Y; Guo F; Liu Y; Huang F; Fan X; Zhao L; Qin G
    Bioengineered; 2022 Feb; 13(2):3911-3929. PubMed ID: 35129424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1‑receptor for advanced glycation end products‑nuclear factor‑κB signaling pathway.
    Yao D; Wang S; Wang M; Lu W
    Mol Med Rep; 2018 Oct; 18(4):3625-3630. PubMed ID: 30132524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.
    Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
    Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
    PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats.
    Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak LO; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
    Diabetes Obes Metab; 2018 Nov; 20(11):2617-2626. PubMed ID: 29923295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High glucose-induced Smad3 linker phosphorylation and CCN2 expression are inhibited by dapagliflozin in a diabetic tubule epithelial cell model.
    Pan X; Phanish MK; Baines DL; Dockrell MEC
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34003249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice.
    Zeng L; Li J; Gao F; Song Y; Wei L; Qu N; Chen S; Zhao X; Lei Z; Cao W; Chen L; Jiang H
    J Cell Mol Med; 2024 Mar; 28(6):e18176. PubMed ID: 38454800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin ameliorates diabetic renal injury through suppressing the self-perpetuating cycle of inflammation mediated by HMGB1 feedback signaling in the kidney.
    Yuan Y; Sun M; Jin Z; Zheng C; Ye H; Weng H
    Eur J Pharmacol; 2023 Mar; 943():175560. PubMed ID: 36736941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renalase contributes to protection against renal fibrosis via inhibiting oxidative stress in rats.
    Wu Y; Wang L; Wang X; Wang Y; Zhang Q; Liu W
    Int Urol Nephrol; 2018 Jul; 50(7):1347-1354. PubMed ID: 29476431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro.
    Baer PC; Koch B; Freitag J; Schubert R; Geiger H
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced
    Hodrea J; Balogh DB; Hosszu A; Lenart L; Besztercei B; Koszegi S; Sparding N; Genovese F; Wagner LJ; Szabo AJ; Fekete A
    Am J Physiol Renal Physiol; 2020 Apr; 318(4):F1017-F1029. PubMed ID: 32116017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.